289 related articles for article (PubMed ID: 12445287)
41. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
[TBL] [Abstract][Full Text] [Related]
42. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.
Michaeli Y; Denkberg G; Sinik K; Lantzy L; Chih-Sheng C; Beauverd C; Ziv T; Romero P; Reiter Y
J Immunol; 2009 May; 182(10):6328-41. PubMed ID: 19414786
[TBL] [Abstract][Full Text] [Related]
43. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
Bronte V; Apolloni E; Ronca R; Zamboni P; Overwijk WW; Surman DR; Restifo NP; Zanovello P
Cancer Res; 2000 Jan; 60(2):253-8. PubMed ID: 10667570
[TBL] [Abstract][Full Text] [Related]
44. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
45. Peptide-based cancer vaccines.
Machiels JP; van Baren N; Marchand M
Semin Oncol; 2002 Oct; 29(5):494-502. PubMed ID: 12407514
[TBL] [Abstract][Full Text] [Related]
46. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
47. Kobner phenomena as a complication of immune therapy of neoplastic disease.
James B
Autoimmunity; 1991; 10(2):165. PubMed ID: 1782328
[No Abstract] [Full Text] [Related]
48. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
49. A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance.
Huard B; Karlsson L
Eur J Immunol; 2000 Jun; 30(6):1665-75. PubMed ID: 10898503
[TBL] [Abstract][Full Text] [Related]
50. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.
Storkus WJ; Herrem C; Kawabe M; Cohen PA; Bukowski RM; Finke JH; Wesa AK
Crit Rev Immunol; 2007; 27(5):485-93. PubMed ID: 18197809
[TBL] [Abstract][Full Text] [Related]
51. [Vaccine strategies against melanoma].
Ghiringhelli F; Zitvogel L
Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
53. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice.
Mullins DW; Bullock TN; Colella TA; Robila VV; Engelhard VH
J Immunol; 2001 Nov; 167(9):4853-60. PubMed ID: 11673489
[TBL] [Abstract][Full Text] [Related]
54. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
55. A commentary on the first international conference on engineered vaccines for cancer and AIDS; the "coming of age" of tumor immunology.
Ada G
Cancer Biother; 1994; 9(1):71-4. PubMed ID: 7529084
[No Abstract] [Full Text] [Related]
56. Specific immunotherapy of cancer in elderly patients.
Matzku S; Zöller M
Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
[TBL] [Abstract][Full Text] [Related]
57. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
Yee C; Thompson JA; Byrd D; Riddell SR; Roche P; Celis E; Greenberg PD
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16168-73. PubMed ID: 12427970
[TBL] [Abstract][Full Text] [Related]
58. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Palmer DC; Chan CC; Gattinoni L; Wrzesinski C; Paulos CM; Hinrichs CS; Powell DJ; Klebanoff CA; Finkelstein SE; Fariss RN; Yu Z; Nussenblatt RB; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 2008 Jun; 105(23):8061-6. PubMed ID: 18523011
[TBL] [Abstract][Full Text] [Related]
59. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.
Wang RF
Immunol Rev; 2002 Oct; 188():65-80. PubMed ID: 12445282
[TBL] [Abstract][Full Text] [Related]
60. Strategies for immunotherapy of cancer.
Melief CJ; Toes RE; Medema JP; van der Burg SH; Ossendorp F; Offringa R
Adv Immunol; 2000; 75():235-82. PubMed ID: 10879286
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
